dc.date.accessioned | 2023-02-10T18:17:51Z | |
dc.date.available | 2023-02-10T18:17:51Z | |
dc.date.created | 2023-01-31T10:26:54Z | |
dc.date.issued | 2022 | |
dc.identifier.citation | Nilsen, Dennis W.T. Røysland, Michelle Ueland, Thor Aukrust, Pål Michelsen, Annika Elisabet Staines, Harry Barvik, Ståle Kontny, Frederic Nordrehaug, Jan Erik Bonarjee, Vernon V S . The Effect of Protease-Activated Receptor-1 (PAR-1) Inhibition on Endothelial-Related Biomarkers in Patients with Coronary Artery Disease. Thrombosis and Haemostasis. 2022 | |
dc.identifier.uri | http://hdl.handle.net/10852/99881 | |
dc.description.abstract | Abstract Background: Vorapaxar has been shown to reduce cardiovascular mortality in postmyocardial infarction (MI) patients. Pharmacodynamic biomarker research related to protease-activated receptor-1 (PAR-1) inhibition with vorapaxar in humans has short follow-up (FU) duration and is mainly focused on platelets rather than endothelial cells. Aim: This article assesses systemic changes in endothelial-related biomarkers during vorapaxar treatment compared with placebo at 30 days’ FU and beyond, in patients with coronary heart disease. Methods: Local substudy patients in Norway were included consecutively from two randomized controlled trials; post-MI subjects from TRA2P-TIMI 50 and non-ST-segment elevation MI (NSTEMI) patients from TRACER. Aliquots of citrated blood were stored at–80°C. Angiopoietin-2, angiopoietin-like 4, vascular endothelial growth factor, intercellular adhesion molecule-1, vascular cell adhesion molecule-1, E-selectin, von Willebrand factor, thrombomodulin, and plasminogen activator inhibitor-1 and -2 were measured at 1-month FU and at study completion (median 2.3 years for pooled patients). Results: A total of 265 consecutive patients (age median 62.0, males 83%) were included. Biomarkers were available at both FUs in 221 subjects. In the total population, angiopoietin-2 increased in patients on vorapaxar as compared with placebo at 1-month FU (p ¼ 0.034). Angiopoietin-like 4 increased (p ¼ 0.028) and plasminogen activator inhibitor-2 decreased (p ¼ 0.025) in favor of vorapaxar at final FU. In postMI subjects, a short-term increase in E-selectin favoring vorapaxar was observed, p ¼ 0.029. Also, a short-term increase in von Willebrand factor (p ¼ 0.032) favoring vorapaxar was noted in NSTEMI patients. Conclusion: Significant endothelial biomarker changes during PAR-1 inhibition were observed in post-MI and NSTEMI patients. | |
dc.description.abstract | The Effect of Protease-Activated Receptor-1 (PAR-1) Inhibition on Endothelial-Related Biomarkers in Patients with Coronary Artery Disease | |
dc.language | EN | |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/ | |
dc.title | The Effect of Protease-Activated Receptor-1 (PAR-1) Inhibition on Endothelial-Related Biomarkers in Patients with Coronary Artery Disease | |
dc.title.alternative | ENEngelskEnglishThe Effect of Protease-Activated Receptor-1 (PAR-1) Inhibition on Endothelial-Related Biomarkers in Patients with Coronary Artery Disease | |
dc.type | Journal article | |
dc.creator.author | Nilsen, Dennis W.T. | |
dc.creator.author | Røysland, Michelle | |
dc.creator.author | Ueland, Thor | |
dc.creator.author | Aukrust, Pål | |
dc.creator.author | Michelsen, Annika Elisabet | |
dc.creator.author | Staines, Harry | |
dc.creator.author | Barvik, Ståle | |
dc.creator.author | Kontny, Frederic | |
dc.creator.author | Nordrehaug, Jan Erik | |
dc.creator.author | Bonarjee, Vernon V S | |
cristin.unitcode | 185,53,48,14 | |
cristin.unitname | Institutt for indremedisinsk forskning | |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 1 | |
dc.identifier.cristin | 2119546 | |
dc.identifier.bibliographiccitation | info:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Thrombosis and Haemostasis&rft.volume=&rft.spage=&rft.date=2022 | |
dc.identifier.jtitle | Thrombosis and Haemostasis | |
dc.identifier.pagecount | 12 | |
dc.identifier.doi | https://doi.org/10.1055/s-0042-1760256 | |
dc.type.document | Tidsskriftartikkel | |
dc.type.peerreviewed | Peer reviewed | |
dc.source.issn | 0340-6245 | |
dc.type.version | PublishedVersion | |